![Calvin Yu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Historique de carrière de Calvin Yu
Anciens postes connus de Calvin Yu
Sociétés | Poste | Début | Fin |
---|---|---|---|
Stemcentrx, Inc.
![]() Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | Comptroller/Controller/Auditor | 01/02/2016 | 01/06/2017 |
ADVERUM BIOTECHNOLOGIES, INC. | Directeur Financier/CFO | 01/09/2014 | 01/02/2016 |
FIVE PRIME THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/03/2010 | 01/09/2014 |
ALECTOR, INC. | Comptroller/Controller/Auditor | - | 08/09/2021 |
Directeur Financier/CFO | 01/06/2017 | 08/09/2021 | |
Corporate Officer/Principal | 08/09/2021 | - |
Formation de Calvin Yu
San Francisco State University | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 6 |
Opérationnelle
Comptroller/Controller/Auditor | 3 |
Director of Finance/CFO | 2 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
ALECTOR, INC. | Health Technology |
ADVERUM BIOTECHNOLOGIES, INC. | Health Technology |
Entreprise privées | 2 |
---|---|
Stemcentrx, Inc.
![]() Stemcentrx, Inc. BiotechnologyHealth Technology Stemcentrx, Inc. develops life-changing therapies for cancer patients. It develops proprietary discovery platforms that yield unprecedented insight into the biology of tumors and are being exploited to develop potent new cancer drugs. The firm specializes in designing drugs to target cancer stem cells, which are the cells that cause cancer to spread throughout the body. The company was founded by Brian Christopher Slingerland, Daniel T. Reiner and Scott J. Dylla in 2008 and is headquartered in San Francisco, CA. | Health Technology |
Five Prime Therapeutics, Inc.
![]() Five Prime Therapeutics, Inc. BiotechnologyHealth Technology Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of novel protein therapeutics. Its product candidates includes, Cabiralizumab (FPA008), Bemarituzumab (FPA144), and FPA150. The FPA008 is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that are developing in rheumatoid arthritis and plan to clinically develop in pigmented villonodular synovitis, or PVNS, and in combination with nivolumab in multiple cancers. The FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that are developing to treat patients with gastric cancer. The FPA150 is a CD8 T cell checkpoint which targets B7-H4 that is developing as a monotherapy in multiple cancers. The company was founded by Lewis T. Williams in December 2001 and is headquartered in South San Francisco, C. | Health Technology |